Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): Multi-institutional registry

Abstract

The purpose of this study was to evaluate the patient tolerance and efficacy of delivering locoregional chemotherapy to metastatic colorectal (MC) hepatic metastases via hepatic trans-arterial approach using irinotecan loaded drug eluting beads. This open-label, multi-center, single arm study included 30 MC patients, who had failed first line therapy. Of the 57 total embolization sessions, 12 (21 of sessions) were associated with adverse reactions during or after the treatment. After a median followup of 9 months, response rates by modified RECIST were 75 at 3 months and 66 at 6 months. Hepatic trans-arterial therapy using Irinotecan loaded DC Bead TM was safe and effective in the treatment of MCC as demonstrated by a minimal complication rate and acceptable tumor response. Copyright © 2009 Robert C. G. Martin et al.